Search

CN-122012336-A - Lactobacillus mucilaginosus with uric acid reducing function and application thereof

CN122012336ACN 122012336 ACN122012336 ACN 122012336ACN-122012336-A

Abstract

The invention discloses a fermented lactobacillus mucilaginosus with uric acid reducing function and application thereof, wherein the fermented lactobacillus mucilaginosus is preserved in China general microbiological culture collection center (CGMCC) with the preservation number of CGMCC No.35505 in the year 2025, month 8 and 4. The fermented lactobacillus mucilaginosus not only has excellent creatinine degradation capability, can reduce serum uric acid, creatinine and urea nitrogen levels of hyperuricemia individuals and relieve liver or kidney injury caused by hyperuricemia individuals, but also can inhibit abnormal changes of flora related to metabolic disorder by improving intestinal flora composition, thereby recovering intestinal micro-ecological steady state. Therefore, the fermented lactobacillus mucilaginosus can be used for preparing uric acid-reducing functional foods, health-care foods or microecological preparations.

Inventors

  • LIU BIN
  • Cai Siqiao
  • HUANG YING
  • ZENG FENG
  • XU YUXIN
  • HUANG ZIRUI

Assignees

  • 福建农林大学

Dates

Publication Date
20260512
Application Date
20260213

Claims (10)

  1. 1. A fermented lactobacillus mucilaginosus 21J with uric acid reducing function is characterized in that the fermented lactobacillus mucilaginosus 21J is preserved in China general microbiological culture collection center (CGMCC) with the preservation number of 35505 and is classified and named as fermented lactobacillus mucilaginosus (Limosilactobacillus fermentum) in the year 2025 and the month 8.
  2. 2. A microbial agent is characterized in that: the microbial agent comprises the lactobacillus mucilaginosus 21J according to claim 1.
  3. 3. Use of the lactobacillus mucilaginosus 21J according to claim 1 or the microbial agent according to claim 2 for the preparation of uric acid lowering products.
  4. 4. Use of a lactobacillus fermentum 21J according to claim 1 or a microbial agent according to claim 2 for the preparation of a inosine degrading product.
  5. 5. Use of the lactobacillus mucilaginosus 21J according to claim 1 or the microbial agent according to claim 2 for the preparation of a food, health food or functional product for regulating intestinal flora and metabolic status.
  6. 6. Use of a lactobacillus mucilaginosus 21J according to claim 1 or a microbial agent according to claim 2 for the preparation of a product for the treatment, prevention or co-treatment of hyperuricemia.
  7. 7. The application according to claim 6, wherein the application comprises at least one of the following actions: (1) Reducing serum uric acid, creatinine, and urea nitrogen levels in hyperuricemia individuals; (2) Reducing liver or kidney damage caused by hyperuricemia individuals; (3) Improving intestinal flora structure of hyperuricemia individuals, and promoting flora recovery to healthy homeostasis.
  8. 8. The method according to claim 3 to 6, wherein the product contains 1X 10 8 CFU/mL~1×10 10 CFU/mL of Lactobacillus mucilaginosus 21J.
  9. 9. The method according to claim 3 to 6, wherein the product comprises feed and medicines.
  10. 10. The method of claim 9, further comprising a food-grade or pharmaceutical acceptable carrier or adjuvant.

Description

Lactobacillus mucilaginosus with uric acid reducing function and application thereof Technical Field The invention belongs to the technical field of microecological preparations, functional foods and metabolic disease intervention, and particularly relates to fermented lactobacillus mucilaginosus with uric acid reducing function and application thereof. Background Hyperuricemia is a common metabolic abnormality caused by excessive uric acid production or reduced excretion in the body, and is an important risk factor for gout, kidney function injury and various metabolic diseases. Along with the change of dietary structure and life style, the incidence of hyperuricemia is in an annual rising trend, and has become an important public health problem affecting the health of people. Uric acid is a final product of purine metabolism, the main sources of which include in vivo endogenous purine metabolism and breakdown of purine substances in the diet. Inosine, hypoxanthine, xanthine, and the like are key intermediates in purine metabolism, with xanthine oxidase (Xanthine Oxidase, XOD) playing an important catalytic role in uric acid production. When uric acid production is increased or excretion is blocked, serum uric acid levels are easily increased, and further increased renal burden and tissue damage are caused. Currently, the intervention modalities clinically used to reduce uric acid levels mainly include drugs that inhibit uric acid production or promote uric acid excretion. However, some drugs may cause liver and kidney dysfunction, gastrointestinal discomfort or anaphylaxis during long-term use, and the long-term use thereof is limited. Therefore, the development of a new uric acid lowering strategy which has high safety and is suitable for long-term intervention has important significance. In recent years, it has been found that intestinal flora plays an important role in the regulation of host purine metabolism and uric acid homeostasis. On the one hand, part of intestinal microorganisms can participate in the metabolism or conversion of purine substances, so that uric acid generation is influenced, and on the other hand, the unbalance of intestinal flora can aggravate inflammatory reaction and intestinal barrier damage, so that the metabolic steady state of an organism is influenced. By regulating the structure of intestinal flora, improving the intestinal microecological environment is considered as a potential metabolic regulation and control way. The fermented lactobacillus mucilaginosus (Limosilactobacillus fermentum) is used as a common lactobacillus, has better acid and bile salt resistance and intestinal canal adaptability, and has certain advantages in the aspect of maintaining intestinal canal microecological balance. The prior researches focus on the effect of regulating the intestinal function or the immune homeostasis, but the fermentation lactobacillus mucilaginosus which has the capability of degrading purine metabolic substrates in vitro, reducing uric acid level in vivo and improving liver and kidney functions and intestinal flora structures at the same time is still limited. Therefore, it is necessary to develop a fermented lactobacillus mucilaginosus with definite uric acid reducing function and intestinal health improving effect, and a new technical approach is provided for long-term and safe intervention of hyperuricemia-related metabolic abnormalities. Disclosure of Invention Aiming at the defects of the prior art, the invention provides the fermented lactobacillus mucilaginosus with uric acid reducing function and the application thereof, and the purine precursor substances are degraded and intestinal microecology is regulated, so that the serum uric acid level is reduced and the hyperuricemia related metabolic state is improved. In order to achieve the above purpose, the invention adopts the following technical scheme: A fermented lactobacillus mucilaginosus 21J with uric acid reducing function is preserved in China general microbiological culture collection center (CGMCC) No.35505 in the 8 th month 4 th 2025, and is classified and named as fermented lactobacillus mucilaginosus (Limosilactobacillus fermentum). A microbial agent comprising lactobacillus mucilaginosus 21J as described above. The application of the fermented lactobacillus mucilaginosus 21J or the microbial agent in preparing uric acid reducing products. The application of the lactobacillus mucilaginosus 21J or the microbial agent in preparing inosine degrading products. The application of the fermented lactobacillus mucilaginosus 21J or the microbial agent in foods, health-care foods or functional products for regulating intestinal flora and metabolic state. The application of the fermented lactobacillus mucilaginosus 21J or the microbial agent in preparing products for treating, preventing or assisting in treating hyperuricemia. Further, the above application includes at least one of the following actions: (1) Reduc